• Citer

Impact of erythropoietin on the reduction of blood transfusions and on survival of lung cancer patients receiving first-line chemotherapy.

par Fonseca, P J;Esteban, Emilio;de Vicente, P;Luque, Miguel;Llorente, Bertrand;Capelan, Marta ;Berros, J P;Crespo, G;Lacave, Ángel Jiménez
Référence Clinical & translational oncology, 10, 7, page (426-432)
Publication Publié, 2008-07

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Anaemia is a common problem in patients with cancer who receive chemotherapy and is normally associated with a negative impact on patients' quality of life (QOL), poor cancer control and diminished survival. In clinical trials, recombinant human erythropoietin has been shown to correct and prevent anaemia, decrease the need for blood transfusions and improve cancer patients' QOL.